<?xml version="1.0" encoding="UTF-8"?>
<p>Spirooliganone from the roots of 
 <italic>Illicium oligandrum</italic> Merr. &amp; Chun (
 <italic>Schisandraceae</italic>), chalconoids from 
 <italic>Glycyrrhiza inflata</italic> Batalin (
 <italic>Leguminosae</italic>) [
 <xref rid="B22-pharmaceuticals-13-00313" ref-type="bibr">22</xref>,
 <xref rid="B62-pharmaceuticals-13-00313" ref-type="bibr">62</xref>], xanthones from 
 <italic>Polygala karensium</italic> Kurz. (
 <italic>Polygalaceae</italic>) [
 <xref rid="B22-pharmaceuticals-13-00313" ref-type="bibr">22</xref>,
 <xref rid="B63-pharmaceuticals-13-00313" ref-type="bibr">63</xref>] and 
 <italic>homosoflavonoids</italic> from 
 <italic>Caesalpinia sappan</italic> L. (
 <italic>Leguminosae</italic>) [
 <xref rid="B22-pharmaceuticals-13-00313" ref-type="bibr">22</xref>,
 <xref rid="B64-pharmaceuticals-13-00313" ref-type="bibr">64</xref>] showed powerful antiviral activity [
 <xref rid="B65-pharmaceuticals-13-00313" ref-type="bibr">65</xref>,
 <xref rid="B66-pharmaceuticals-13-00313" ref-type="bibr">66</xref>], determining the prospects of using secondary plant metabolites both for inhibiting the growth of influenza cells and possibly coronavirus infection, and for therapeutic purposes.
</p>
